BaastrupP., HollnagelP., Sorenson, SchouM.: Adverse reactions in treatment with lithium carbonate and haloperidol.JAMA, 236(23): 2645–2646, 6 Dec 1976.
3.
DemersR., LukishR., Pritchard: Convulsion during lithium therapy.Lancet, 2: 315–316, 8 Aug 1970.
4.
DonlonP.T., HopkinJ., TupinJ.P.: Overview: Efficacy and safety of the rapid neuroleptization method with injectable haloperidol.Am J Psychiatry, 136(3): 273–278, 1979.
5.
DunnerD.L., FieveR.R.: Clinical factors in lithium carbonate prophylaxis failure.Arch Gen Psychiatry, 30: 229–233, 1974.
6.
GerleB.: Clinical observations of the side effects of haloperidol.Acta Psychiatr Scand, 40: 65–76, 1964.
7.
GoodmanL.S., GilmanA.: The Pharmacological Basis of Therapeutics5th edition, New York: Macmillan Co., 1975, p. 166.
PrienR.F., CaffeyE.M., KlettC.J.: Factors associated with treatment success in lithium carbonate prophylaxis.Arch Gen Psychiatry, 31: 189–192, 1974.
13.
SingerI., RotenbergD.: Mechanisms of lithium action.N Engl J Med, 289(5): 254–260, 2 Aug 1973.
14.
StrayhornJ.M., NashJ.L.: Severe neurotoxicity despite “therapeutic” serum lithium levels.Dis Nerv Syst, 38: 107–111, Feb. 1977.
15.
TilkianA., SchroederJ.S., KaoJ.J., HultgrenH.N.: The cardiovascular effects of lithium in man: a review of the literature.Am J Med, 61: 665–670, Nov 1976.